Infantile hemangioma: current classification, clinical picture and effective methods of therapy


Cite item

Full Text

Abstract

Review of the literature devoted to one of the most common tumors of childhood - hemangioma is presented. Literature search was performed using the NCBI, including PubMed, PubMed Health, and The Cochrane Library databases. Infantile hemangioma is a neoplastic proliferation of endothelial cells, which is characterized by different phases of development: proliferation and spontaneous involution. The types of infantile hemangiomas, variants of the course and possible complications such as ulceration, functional disorders, and the formation of cosmetic defects are described. Incidence associated with infantile hemangioma syndrome is presented. The current views on the pathogenesis of infantile hemangiomas are described. Information about the best methods of diagnostic imaging, as well as medical and surgical therapies, including systemic and topical therapy with β-blockers, corticosteroids and use of lasers are described.

About the authors

Oleg V. Sheptiy

Institute of Plastic Surgery and Cosmetology

Email: shov63@mail.ru
MD, PhD, Institute of Plastic Surgery and Cosmetology Moscow, 105066, Russian Federation

L. S Kruglova

Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Department of Health

Moscow, 107564, Russian Federation

References

  1. Bruckner A.L., Frieden I.J. Hemangiomas of infancy. J. Am. Acad. Dermatol. 2003; 48(4): 477-93.
  2. Kilcline C., Frieden I.J. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr. Dermatol. 2008; 25(2): 168- 73. PMID: 18429772.
  3. Enjolras O., Garzon M.C. Vascular stains, malformations, and tumors. In: Eichenfield L.F., Frieden I.J., Esterly N.B., eds. Neonatal Dermatology. 2nd ed. Philadelphia: Saunders Elsevier; 2008.
  4. Wassef M., Blei F., Adams D., Alomari A., Baselga E., Berenstein A., et al.; ISSVA Board and Scientific Committee. Vascular Anomalies Classification: Recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015; 136(1): e203--14. doi: 10.1542/peds.2014-3673.
  5. Drolet B.A., Swanson E.A., Frieden I.J.; Hemangioma Investigator Group. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J. Pediatr. 2008; 153(5): 712-5. doi: 10.1016/j.jpeds.2008.05.043.
  6. Colonna V., Resta L., Napoli A., Bonifazi E. Placental hypoxia and neonatal haemangioma: clinical and histological observations. Br. J. Dermatol. 2010; 162(1): 208-9. doi: 10.1111/j.1365-2133.2009.09493.x.
  7. Folkman J. Proceeding: Tumor angiogenesis factor. Cancer Res. 1974; 34(8): 2109-13.
  8. Barnés C.M., Christison-Lagay E.A., Folkman J. The placenta theory and the origin of infantile hemangioma. Lymphat. Res. Biol. 2007; 5(4): 245-55. doi: 10.1089/lrb.2007.1018.
  9. Hoeger P.H., Maerker J.M., Kienast A.K., Syed S.B., Harper J.I. Neonatal haemangiomatosis associated with placental chorioangiomas: report of three cases and review of the literature. Clin. Exp. Dermatol. 2009; 34(5): e78-80. doi: 10.1111/j.1365-2230.2009.03221.x.
  10. Haggstrom A.N., Lammer E.J., Schneider R.A., Marcucio R., Frieden I.J. Patterns of infantile hemangioma: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006; 117(3): 698-703.
  11. Haggstrom A.N., Garzon M.C., Baselga E., Chamlin S.L., Frieden I.J., Holland K., et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010; 126(2): e418-26. doi: 10.1542/peds.2009-3166.
  12. Heyer G.L. PHACE(S) syndrome. Handb. Clin. Neurol. 2015; 132: 169-83. doi: 10.1016/B978-0-444-62702-5.00012-3.
  13. Girard C., Bigorre M., Guillot B., Bessis D. PELVIS syndrome. Arch. Dermatol. 2006; 142(7): 884-8.
  14. Waner M., North P.E., Scherer K.A., Frieden I.J., Waner A., Mihm M.C. Jr. The nonrandom distribution of facial hemangiomas. Arch. Dermatol. 2003; 139(7): 869-75.
  15. Mulliken J.B., Burrows P.E., Fishman S.J., eds. Mulliken and Young’s Vascular Anomalies Hemangiomas and Malformations. 2nd ed. New York: Oxford University Press; 2013.
  16. Chiller K.G., Passaro D., Frieden I.J. Hemangiomas of infancy: Clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch. Dermatol. 2002; 138(12): 1567-76.
  17. Frieden I.J., Haggstrom A.N., Drolet B.A., Mancini A.J., Friedlander S.F., Boon L., et al. Infantile hemangiomas: Current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr. Dermatol. 2005; 22(5): 383-406.
  18. Mulliken J.B., Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J. Am. Acad. Dermatol. 2004; 50(6): 875-82.
  19. Chang L.C., Haggstrom A.N., Drolet B.A., Baselga E., Chamlin S.L., Garzon M.C., et al.; Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: Implications for management. Pediatrics. 2008; 122(2): 360-7. doi: 10.1542/peds.2007-67.
  20. Donnelly L.F., Bissettz G.S. 3rd, Adams D.M. Combined sonographic and fluoroscopic guidance: a modified technique for percutaneous sclerosis of low-flow vascular malformations. Am. J. Roentgenol. 1999; 173(3): 655-7.
  21. Gold L., Nazarian L.N., Johar A.S., Rao V.M. Characterization of maxillofacial soft tissue vascular anomalies by ultrasound and color Doppler imaging: An adjuvant to computed tomography and magnetic resonance imaging. J. Oral. Maxillofac. Surg. 2003; 61(1): 19-31.
  22. Dubois J., Alison M. Vascular anomalies: what a radiologist needs to know. Pediatr. Radiol. 2010; 40(6): 895-905. doi: 10.1007/s00247-010-1621-y.
  23. Bhat V., Salins P.C., Bhat V. Imaging spectrum of hemangioma and vascular malformations of the head and neck in children and adolescents. J. Clin. Imaging Sci. 2014; 4: 31. doi: 10.4103/2156-7514.135179.
  24. Siegel M.J. Magnetic resonance imaging of musculoskeletal soft tissue masses. Radiol. Clin. North Am. 2001; 39(4): 701-20.
  25. Holland K.E., Drolet B.A. Approach to the patient with an infantile hemangioma. Dermatol. Clin. 2013; 31(2): 289-301.
  26. Chen T.S., Eichenfield L.F., Friedlander S.F. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013; 131(1): 99-108.
  27. Haggstrom A.N., Drolet B.A., Baselga E., Chamlin S.L., Garzon M.C., Horii K.A., et al. Prospective study of infantile hamangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006; 118(3): 882-7.
  28. Hermans D.J., Boezeman J.B., Van de Kerkhof P.C., Rieu P.N., Van der Vleuten C.J. Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases. Eur. J. Dermatol. 2009; 19(2):152-6. doi: 10.1684/ejd.2008.0576.
  29. Pandey A., Gangopadhyay A.N., Sharma S.P., Kumar V., Gopal S.C., Gupta D.K. Conservative management of ulcerated haemangioma: twenty years’ experience. Int. Wound J. 2009; 6(1): 59-62. doi: 10.1111/j.1742-481X.2008.00562.x.
  30. Luu M., Frieden I.J. Haemangioma: clinical course, complications and management. Br. J. Dermatol. 2013; 169(1): 20-30.
  31. Schwartz S.R., Blei F., Ceisler E., Steele M, Furlan L, Kodsi S. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. J. AAPOS. 2006; 10(3): 262-8.
  32. Bramhall R.J., Quaba A. A review of 58 patients with periorbital haemangiomas to determine appropriate cases for intervention. J. Plast. Reconstr. Aesthet. Surg. 2008; 61(2): 138-49.
  33. Rahbar R., Nicollas R., Roger G., Triglia J.M., Garabedian E.N., McGill T.J., Healy G.B. The biology and management of subglottic hemangioma: past, present, future. Laryngoscope. 2004; 114(11): 1880-91.
  34. Orlow S.J., Isakoff M.S., Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. J. Pediatr. 1997; 131(4): 643-6.
  35. Hoger P.H., Harper J. Kinderdermatologie: Differenzialdiagnostik und Therapie bei Kindern und Jugendlichen. Stuttgart: Schattauer; 2011.
  36. Leaute-Labreze C., Dumas de la Roque E., Hubiche T., Boralevi F., Thambo J.B., Taieb A. Propranolol for severe hemangiomas of infancy. N. Engl. J. Med. 2008; 358(24): 2649-51. doi: 10.1056/NEJMc0708819.
  37. Sans V., de la Roque E.D., Berge J., Grenier N., Boralevi F., Mazereeuw-Hautier J., et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009; 124(3): e423-31. doi: 10.1542/peds.2008-3458.
  38. Hogeling M., Adams S., Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011; 128(2): e259-66.
  39. Georgountzou A., Karavitakis E., Klimentopoulou A., Xaidara A., Kakourou T. Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. Acta Paediatr. 2012; 101(10): e469-74. doi: 10.1111/j.1651-2227.2012.02783.x.
  40. Chim H., Armijo B.S., Miller E., Gliniak C., Serret M.A., Gosain A.K. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann. Surg. 2012; 256(1): 146-56. doi: 10.1097/SLA.0b013e318254ce7a.
  41. Storch C.H., Hoeger P.H. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br. J. Dermatol. 2010; 163(2): 269-74.
  42. Drolet B.A., Frommelt P.C., Chamlin S.L., Haggstrom A., Bauman N.M., Chiu Y.E., et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013; 131(1): 128-40. doi: 10.1542/peds.2012-1691.
  43. Marqueling A.L., Oza V., Frieden I.J., Puttgen K.B. Propranolol and infantile hemangiomas four years later: a systemic review. Pediatr. Dermatol. 2013; 30(2): 182-91.
  44. Admani S., Feldstein S., Gonzalez E.M., Friedlander S.F. Beta blockers: an innovation in the treatment of infantile hemangiomas. J. Clin. Aesthet. Dermatol. 2014; 7(7): 37-45.
  45. Bagazgoitia L., Torrelo A., Gutierrez J.C., Hernandez-Martin A., Luna P., Gutierrez M., et al. Propranolol for infantile hemangiomas. Pediatr. Dermatol. 2011; 28(2): 108-14.
  46. Sondhi V., Patnaik S.K. Propranolol for Infantile Hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. J. Pediatr. Hematol. Oncol. 2013; 35(7): 493-9.
  47. Bagazgoitia L., Hernandez-Martin A., Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr. Dermatol. 2011; 28(6): 658-62.
  48. Ni N., Langer P., Wagner R., Guo S. Topical timolol for periocular hemangioma: report of further study. Arch. Ophthalmol. 2011; 129(3): 373-9. doi: 10.1001/archophthalmol.2011.24.
  49. Thomas J., Kumar P., Kumar D.D. Ulcerated infantile haemangioma of buttock successfully treated with topical timolol. J. Cutan. Aesthet. Surg. 2013; 6(3): 168-9. doi: 10.4103/0974-2077.118432.
  50. Chakkittakandiyil A., Phillips R., Frieden I.J., Siegfried E., Lara-Corrales I., Lam J., et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr. Dermatol. 2012; 29(1): 28-31. doi: 10.1111/j.1525-1470.2011.01664.x.
  51. Semkova K., Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study. Clin. Exper. Dermatol. 2013; 38(2): 143-6.
  52. Greene A.K., Couto R.A. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plast. Reconstr. Surg. 2011; 128(3): 743-52.
  53. Jalil S., Akhtar J., Ahmed S. Corticosteroids therapy in the management of infantile cutaneous hemangiomas. J. Coll. Physicians Surg. Pak. 2006; 16(10): 662-5.
  54. Witman P.M., Wagner A.M., Scherer K., Waner M., Frieden I.J. Complications following pulse dye laser treatment of superficial hemangiomas. Lasers Surg. Med. 2006; 38(2): 116-23.
  55. David L.R., Malet M.M., Argenta L.C. Efficacy of pulse dye laser therapy for the treatment of ulceratd haemagiomas: a review of 78 patients. Br. J. Plast. Surg. 2003; 56(4): 317-27.
  56. Di Maio L., Baldi A., Dimaio V., Barzi A. Use of flashlamp-pumped pulsed dye laser in the treatment of superficial vascular malformations and ulcerated hemangiomas. In Vivo. 2011; 25(1): 117-23.
  57. Admani S., Krakowski A.C., Nelson J.S., Eichenfield L.F., Friedlander S.F. Beneficial effects of early pulsed dye laser therapy in individuals with infantile hemangiomas. Dermatol. Surg. 2012; 38(10): 1732-8. doi: 10.1111/j.1524-4725.2012.02487.x.
  58. Asilian A., Mokhtari F., Kamali A.S., Abtahi-Naeini B., Nilforoushzadeh M.A., Mostafaie S. Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial. Adv. Biomed. Res. 2015; 4: 257. doi: 10.4103/2277-9175.170682.
  59. Vlachakis I., Gardikis S., Michailoudi E., Charissis G. Treatment of hemangiomas in children using a Nd:YAG laser in conjunction with ice cooling of the epidermis: techniques and results. BMC Pediatr. 2003; 3: 2.
  60. Waldschmidt J., Giest H., Meyer L. Endoscopic laser application in 56 children with hemangiomas of the larynx and trachea. Med. Laser Appl. 2005; 20(4): 297-302.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies